Cargando…
Intranasal HBsAg/HBcAg-Containing Vaccine Induces Neutralizing Anti-HBs Production in Hepatitis B Vaccine Non-Responders
Hepatitis B vaccine induces the production of antibodies against hepatitis B surface antigen (anti-HBs) and prevents hepatitis B virus (HBV) infection. However, 5–10% of individuals cannot develop anti-HBs even after multiple vaccinations (HB vaccine non-responders). We developed an intranasal vacci...
Autores principales: | , , , , , , , , , , , , , , |
---|---|
Formato: | Online Artículo Texto |
Lenguaje: | English |
Publicado: |
MDPI
2023
|
Materias: | |
Acceso en línea: | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC10535445/ https://www.ncbi.nlm.nih.gov/pubmed/37766155 http://dx.doi.org/10.3390/vaccines11091479 |
_version_ | 1785112631032414208 |
---|---|
author | Shiraishi, Kana Yoshida, Osamu Imai, Yusuke Akbar, Sheikh Mohammad Fazle Sanada, Takahiro Kohara, Michinori Miyazaki, Takashi Kamishita, Taizou Miyake, Teruki Hirooka, Masashi Tokumoto, Yoshio Abe, Masanori Rubido, Julio Cesar Aguilar Nieto, Gerardo Guillen Hiasa, Yoichi |
author_facet | Shiraishi, Kana Yoshida, Osamu Imai, Yusuke Akbar, Sheikh Mohammad Fazle Sanada, Takahiro Kohara, Michinori Miyazaki, Takashi Kamishita, Taizou Miyake, Teruki Hirooka, Masashi Tokumoto, Yoshio Abe, Masanori Rubido, Julio Cesar Aguilar Nieto, Gerardo Guillen Hiasa, Yoichi |
author_sort | Shiraishi, Kana |
collection | PubMed |
description | Hepatitis B vaccine induces the production of antibodies against hepatitis B surface antigen (anti-HBs) and prevents hepatitis B virus (HBV) infection. However, 5–10% of individuals cannot develop anti-HBs even after multiple vaccinations (HB vaccine non-responders). We developed an intranasal vaccine containing both HBs antigen (HBsAg) and HB core antigen (HBcAg) and mixed it with a viscosity enhancer, carboxyl vinyl polymer (CVP-NASVAC). Here, we investigated the prophylactic capacity of CVP-NASVAC in HB vaccine non-responders. Thirty-four HB vaccine non-responders were administered three doses of intranasal CVP-NASVAC. The prophylactic capacity of CVP-NASVAC was assessed by evaluating the induction of anti-HBs and anti-HBc (IgA and IgG) production, HBV-neutralization activity of sera, and induction of HBs- and HBc-specific cytotoxic T lymphocytes (CTLs). After CVP-NASVAC administration, anti-HBs and anti-HBc production were induced in 31/34 and 27/34 patients, respectively. IgA anti-HBs and anti-HBc titers significantly increased after CVP-NASVAC vaccination. HBV-neutralizing activity in vitro was confirmed in the sera of 26/29 CVP-NASVAC-administered participants. HBs- and HBc-specific CTL counts substantially increased after the CVP-NASVAC administration. Mild adverse events were observed in 9/34 participants; no serious adverse events were reported. Thus, CVP-NASVAC could be a beneficial vaccine for HB vaccine non-responders. |
format | Online Article Text |
id | pubmed-10535445 |
institution | National Center for Biotechnology Information |
language | English |
publishDate | 2023 |
publisher | MDPI |
record_format | MEDLINE/PubMed |
spelling | pubmed-105354452023-09-29 Intranasal HBsAg/HBcAg-Containing Vaccine Induces Neutralizing Anti-HBs Production in Hepatitis B Vaccine Non-Responders Shiraishi, Kana Yoshida, Osamu Imai, Yusuke Akbar, Sheikh Mohammad Fazle Sanada, Takahiro Kohara, Michinori Miyazaki, Takashi Kamishita, Taizou Miyake, Teruki Hirooka, Masashi Tokumoto, Yoshio Abe, Masanori Rubido, Julio Cesar Aguilar Nieto, Gerardo Guillen Hiasa, Yoichi Vaccines (Basel) Article Hepatitis B vaccine induces the production of antibodies against hepatitis B surface antigen (anti-HBs) and prevents hepatitis B virus (HBV) infection. However, 5–10% of individuals cannot develop anti-HBs even after multiple vaccinations (HB vaccine non-responders). We developed an intranasal vaccine containing both HBs antigen (HBsAg) and HB core antigen (HBcAg) and mixed it with a viscosity enhancer, carboxyl vinyl polymer (CVP-NASVAC). Here, we investigated the prophylactic capacity of CVP-NASVAC in HB vaccine non-responders. Thirty-four HB vaccine non-responders were administered three doses of intranasal CVP-NASVAC. The prophylactic capacity of CVP-NASVAC was assessed by evaluating the induction of anti-HBs and anti-HBc (IgA and IgG) production, HBV-neutralization activity of sera, and induction of HBs- and HBc-specific cytotoxic T lymphocytes (CTLs). After CVP-NASVAC administration, anti-HBs and anti-HBc production were induced in 31/34 and 27/34 patients, respectively. IgA anti-HBs and anti-HBc titers significantly increased after CVP-NASVAC vaccination. HBV-neutralizing activity in vitro was confirmed in the sera of 26/29 CVP-NASVAC-administered participants. HBs- and HBc-specific CTL counts substantially increased after the CVP-NASVAC administration. Mild adverse events were observed in 9/34 participants; no serious adverse events were reported. Thus, CVP-NASVAC could be a beneficial vaccine for HB vaccine non-responders. MDPI 2023-09-12 /pmc/articles/PMC10535445/ /pubmed/37766155 http://dx.doi.org/10.3390/vaccines11091479 Text en © 2023 by the authors. https://creativecommons.org/licenses/by/4.0/Licensee MDPI, Basel, Switzerland. This article is an open access article distributed under the terms and conditions of the Creative Commons Attribution (CC BY) license (https://creativecommons.org/licenses/by/4.0/). |
spellingShingle | Article Shiraishi, Kana Yoshida, Osamu Imai, Yusuke Akbar, Sheikh Mohammad Fazle Sanada, Takahiro Kohara, Michinori Miyazaki, Takashi Kamishita, Taizou Miyake, Teruki Hirooka, Masashi Tokumoto, Yoshio Abe, Masanori Rubido, Julio Cesar Aguilar Nieto, Gerardo Guillen Hiasa, Yoichi Intranasal HBsAg/HBcAg-Containing Vaccine Induces Neutralizing Anti-HBs Production in Hepatitis B Vaccine Non-Responders |
title | Intranasal HBsAg/HBcAg-Containing Vaccine Induces Neutralizing Anti-HBs Production in Hepatitis B Vaccine Non-Responders |
title_full | Intranasal HBsAg/HBcAg-Containing Vaccine Induces Neutralizing Anti-HBs Production in Hepatitis B Vaccine Non-Responders |
title_fullStr | Intranasal HBsAg/HBcAg-Containing Vaccine Induces Neutralizing Anti-HBs Production in Hepatitis B Vaccine Non-Responders |
title_full_unstemmed | Intranasal HBsAg/HBcAg-Containing Vaccine Induces Neutralizing Anti-HBs Production in Hepatitis B Vaccine Non-Responders |
title_short | Intranasal HBsAg/HBcAg-Containing Vaccine Induces Neutralizing Anti-HBs Production in Hepatitis B Vaccine Non-Responders |
title_sort | intranasal hbsag/hbcag-containing vaccine induces neutralizing anti-hbs production in hepatitis b vaccine non-responders |
topic | Article |
url | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC10535445/ https://www.ncbi.nlm.nih.gov/pubmed/37766155 http://dx.doi.org/10.3390/vaccines11091479 |
work_keys_str_mv | AT shiraishikana intranasalhbsaghbcagcontainingvaccineinducesneutralizingantihbsproductioninhepatitisbvaccinenonresponders AT yoshidaosamu intranasalhbsaghbcagcontainingvaccineinducesneutralizingantihbsproductioninhepatitisbvaccinenonresponders AT imaiyusuke intranasalhbsaghbcagcontainingvaccineinducesneutralizingantihbsproductioninhepatitisbvaccinenonresponders AT akbarsheikhmohammadfazle intranasalhbsaghbcagcontainingvaccineinducesneutralizingantihbsproductioninhepatitisbvaccinenonresponders AT sanadatakahiro intranasalhbsaghbcagcontainingvaccineinducesneutralizingantihbsproductioninhepatitisbvaccinenonresponders AT koharamichinori intranasalhbsaghbcagcontainingvaccineinducesneutralizingantihbsproductioninhepatitisbvaccinenonresponders AT miyazakitakashi intranasalhbsaghbcagcontainingvaccineinducesneutralizingantihbsproductioninhepatitisbvaccinenonresponders AT kamishitataizou intranasalhbsaghbcagcontainingvaccineinducesneutralizingantihbsproductioninhepatitisbvaccinenonresponders AT miyaketeruki intranasalhbsaghbcagcontainingvaccineinducesneutralizingantihbsproductioninhepatitisbvaccinenonresponders AT hirookamasashi intranasalhbsaghbcagcontainingvaccineinducesneutralizingantihbsproductioninhepatitisbvaccinenonresponders AT tokumotoyoshio intranasalhbsaghbcagcontainingvaccineinducesneutralizingantihbsproductioninhepatitisbvaccinenonresponders AT abemasanori intranasalhbsaghbcagcontainingvaccineinducesneutralizingantihbsproductioninhepatitisbvaccinenonresponders AT rubidojuliocesaraguilar intranasalhbsaghbcagcontainingvaccineinducesneutralizingantihbsproductioninhepatitisbvaccinenonresponders AT nietogerardoguillen intranasalhbsaghbcagcontainingvaccineinducesneutralizingantihbsproductioninhepatitisbvaccinenonresponders AT hiasayoichi intranasalhbsaghbcagcontainingvaccineinducesneutralizingantihbsproductioninhepatitisbvaccinenonresponders |